ticagrelor

Details

Files

Generic Name:

ticagrelor

Project Status:

Complete

Therapeutic Area:

Prevention of atherothrombotic events with history of myocardial infarction

Manufacturer:

AstraZeneca Canada Inc

Call for patient/clinician input open:

January 15, 2016

Brand Name:

Brilinta

Project Line:

Reimbursement Review

Project Number:

SR0474-000

Call for patient/clinician input closed:

March 7, 2016

NOC Status at Filing:

Pre NOC

Performance Metric:

Achieved

Submission Type:

Initial

Indications:

Prevention of atherothrombotic events with history of myocardial infarction

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

August 25, 2016

Last Updated : October 10, 2018